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Abstract 
Aims: We aimed to (1) assess the association between lipoprotein(a) [Lp(a)] concentration and incident type-2 
diabetes in the Bruneck study, a prospective population-based study, and (2) combine findings with evidence from 
published studies in a literature-based meta-analysis.
Methods: We used Cox proportional hazards models to calculate hazard ratios (HR) for incident type-2 diabetes over 
20 years of follow-up in 815 participants of the Bruneck study according to their long-term average Lp(a) concentra-
tion. For the meta-analysis, we searched Medline, Embase and Web of Science for relevant prospective cohort studies 
published up to October 2016.
Results: In the Bruneck study, there was a 12% higher risk of type-2 diabetes for a one standard deviation lower 
concentration of log Lp(a) (HR = 1.12 [95% CI 0.95–1.32]; P = 0.171), after adjustment for age, sex, alcohol consump-
tion, body mass index, smoking status, socioeconomic status, physical activity, systolic blood pressure, HDL choles-
terol, log high-sensitivity C-reactive protein and waist–hip ratio. In a meta-analysis involving four prospective cohorts 
with a total of 74,575 participants and 4514 incident events, the risk of type-2 diabetes was higher in the lowest two 
quintiles of Lp(a) concentrations (weighted mean Lp(a) = 3.3 and 7.0 mg/dL, respectively) compared to the highest 
quintile (62.9 mg/dL), with the highest risk of type-2 diabetes seen in quintile 1 (HR = 1.28 [1.14–1.43]; P < 0.001).
Conclusions: The current available evidence from prospective studies suggests that there is an inverse association 
between Lp(a) concentration and risk of type-2 diabetes, with a higher risk of type-2 diabetes at low Lp(a) concentra-
tions (approximately <7 mg/dL).
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Background
Elevated lipoprotein(a) [Lp(a)] concentrations have 
been implicated in cardiovascular disorders, with strong 
evidence from prospective cohort studies and Mende-
lian randomisation (MR) studies suggesting a causal 
relationship between high concentrations of Lp(a) and 
increased risk of cardiovascular disease (CVD) [1–4]. In 
contrast, its relationship with incident type-2 diabetes 
is less clear. The first prospective study on this topic [5] 
showed evidence of an inverse relationship between Lp(a) 
concentration and incident type-2 diabetes. Participants 
in the highest quintile (>45.3 mg/dL) of Lp(a) concentra-
tion had a lower risk of type-2 diabetes compared to those 
in the lowest quintile (<3.9  mg/dL) of Lp(a) (HR =  0.78 
[95% CI 0.67–0.91]). Since then, three additional pro-
spective studies have reported findings consistent with 
Open Access
Cardiovascular Diabetology
*Correspondence:  peter.willeit@i-med.ac.at 
†Ellie Paige and Katya L. Masconi contributed equally to this work 
6 Department of Neurology, Medical University of Innsbruck, Innsbruck, 
Austria
Full list of author information is available at the end of the article
Page 2 of 11Paige et al. Cardiovasc Diabetol  (2017) 16:38 
an inverse relationship between Lp(a) levels and incident 
type-2 diabetes [6–9]. The question of whether this is a 
causal relationship is of clinical importance since drugs 
that selectively reduce Lp(a) are now available [10].
Lp(a) is composed of an LDL-like particle linked to 
apolipoprotein(a) [apo(a)] [11]. Blood concentrations 
vary widely among individuals and are highly skewed 
rightward at the population level [11]. Lp(a) levels are 
primarily under genetic control, with genetic variants 
and the number of kringle IV-2 (KIV-2) repeats in the 
LPA gene accounting for much of the variability in Lp(a) 
concentrations [11]. KIV-2 repeats are translated into 
apo(a) isoforms with low numbers of repeats resulting 
in small apo(a) isoforms and higher numbers of repeats 
resulting in large apo(a) isoforms [11].
Unlike observational studies which can be affected by 
residual confounding and reverse causality, MR studies 
use genetic variants as proxies for the exposure to assess 
causality [12]. Under the principle of independent assort-
ment, genetic variants are not associated with confound-
ing factors and are not subject to reverse causality when 
assessed in relation to a disease outcome since variants are 
randomly assorted during meiosis [13]. Two MR studies 
have assessed the relationship between Lp(a) and type-2 
diabetes and found a null association between the variant 
rs10455872, mainly found in European cohorts, and risk of 
incident diabetes [6, 9]. The rs10455872 variant is associ-
ated with small apo(a) isoforms and high Lp(a) levels [11] 
and has been previously shown to be strongly associated 
with an increased risk of CVD [14]. However, rs10455872 
tags individuals with a wide range of Lp(a) concentrations 
and is suggested to be an imprecise proxy for assessing cau-
sality between low Lp(a) levels and diabetes [11, 15]. The 
MR study by Kamstrup and Nordestgaard [6] also assessed 
the sum of KIV-2 repeats of both apo(a) alleles, finding that 
the highest quintile of the sum of KIV-2 repeats, which are 
associated with larger apo(a) isoforms and lower levels of 
Lp(a), were associated with a 16% increased risk of type-2 
diabetes compared to the lowest four quintiles (OR 1.16 
[95% CI 1.05–1.28]) [6]. A causal relationship between low 
levels of Lp(a) concentration and increased risk of type-2 
diabetes cannot be ruled out based on these findings.
The aims of the present study were two-fold. First, to 
examine the relationship between long-term average lev-
els of Lp(a) concentration and incident type-2 diabetes in 
the Bruneck study. Second, to conduct a meta-analysis 
combining results from the Bruneck study with results 
from the previously published studies.
Methods
Bruneck study population
The Bruneck Study is a prospective population-
based survey of the epidemiology and pathogenesis of 
atherosclerosis [16, 17]. The study design and survey 
have been described in detail elsewhere [18–20]. Briefly, 
in 1990, a random sample of 1000 men and women aged 
40–79 years living in the city of Bruneck (125 per sex and 
decade of age) were invited to participate in the study. A 
total of 936 men and women were enrolled and re-exam-
ined every five years since. The participants in this study 
had access to one public health care system, the Bruneck 
Hospital which is the only health care provider in the 
region. The network existing between hospital and prac-
titioners allowed for the retrieval of full medical infor-
mation of all individuals. The follow-up rate was 99.9% 
regarding clinical end points.
Ascertainment of type‑2 diabetes
At baseline, type-2 diabetes was diagnosed using the 
World Health Organization (WHO) criteria [21]; a fast-
ing glucose ≥126 mg/dL, a 2-h oral glucose tolerance test 
(OGTT) ≥200 mg/dL after a standard 75-g glucose load 
or a clinical diagnosis of diabetes with the use of medica-
tion and/or diet modification. At subsequent follow-ups, 
OGTTs were not performed. Instead, diagnosis of type-2 
diabetes was ascertained using the American Diabetes 
Association (ADA) criteria [22].
Clinical and laboratory data
At baseline and each 5-year follow-up, sociodemographic 
characteristics, comorbidities and medication use were 
recorded. Data were retrieved with a clinical history and 
medical record review, a complete physical examination, 
and laboratory measures. Body mass index (BMI), waist–
hip ratio (WHR), smoking status, alcohol consumption 
and blood pressure were assessed using validated stand-
ard procedures. Physical activity was recorded by com-
posed score for work (three categories) and sports/leisure 
activities (0, ≤2, and  >2  h/week). Socioeconomic status 
(SES) was categorized on a three-category scale (low, 
medium, and high) based on information about occu-
pational status and educational level of the person with 
the highest income in the household. Venous blood sam-
ples were drawn after an overnight fast and abstinence 
from smoking. Total cholesterol, low density lipoprotein 
cholesterol (LDL-C), high density lipoprotein choles-
terol (HDL-C), and high-sensitivity C-reactive protein 
(hsCRP) were all assessed by standard methods. Since 
LDL-C was estimated with the Friedwald formula and is 
therefore affected by the cholesterol content of Lp(a), we 
calculated corrected LDL-C by subtracting Lp(a) mass in 
mg/dL and multiplying by 0.45 [23]. Lp(a) was measured 
in fasted samples by a double-antibody ELISA (Immuno) 
using a polyclonal anti-apo(a) for capture and a monova-
lent anti-apo(a) Fab fragment coupled with peroxidase 
for detection. Lp(a) testing was repeated in 1995 using an 
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updated, more sensitive method. As previously described 
[24], apo(a) phenotyping was performed by sodium 
dodecyl sulfate–agarose gel electrophoresis (SDS aga-
rose) under reducing conditions [23].
Bruneck study statistical analysis
We analysed data from individuals without a baseline 
diagnosis of diabetes and with Lp(a) concentration meas-
ured at baseline. Baseline characteristics of participants 
were examined. Continuous variables were presented as 
mean (standard deviation [SD]) or medians (interquartile 
range [IQR]) and dichotomous variables as percentages. 
Linear regression was used to determine the percent-
age mean difference in log transformed baseline Lp(a) 
levels per SD increase in the baseline characteristics. To 
account for the skewed distribution of Lp(a) concentra-
tion, we log-transformed Lp(a) levels and estimated 
usual levels by regressing the log-transformed Lp(a) val-
ues measured at the 5-year follow-up on the log-trans-
formed Lp(a) baseline values [25, 26]. Participants were 
grouped into Lp(a) categories based on these usual val-
ues and cut-points defined by quintiles of baseline Lp(a) 
concentration.
Cox proportional hazards regression was used to esti-
mate adjusted hazard ratios (HR) and 95% confidence 
intervals (CI) for the risk of diabetes per SD lower log 
Lp(a) level and by quintiles of Lp(a) concentration, with 
quintile 5 as the reference group. A 1-SD lower log Lp(a) 
level corresponded to a 3.5-fold difference on the origi-
nal scale (i.e., e1.3). Model 1 was adjusted for age and 
sex; Model 2 was further adjusted for alcohol consump-
tion, BMI, smoking status, SES and physical activity; and 
Model 3 was further adjusted for systolic blood pressure, 
HDL-C, log hsCRP and waist–hip ratio. We also investi-
gated the association between apo(a) isoform size (large 
isoforms vs. small [reference group] using a cut-point 
of 22) and incident diabetes risk using Cox models and 
adjusting for the same covariates used in Model 3.
We investigated the potential role of reverse causal-
ity and residual confounding in the Lp(a)-diabetes rela-
tionship using a series of sensitivity analyses. We re-ran 
Model 3 with (1) additional adjustment for fasting glu-
cose; (2) additional adjustment for HbA1c; (3) additional 
adjustment for fasting glucose and HbA1c; (4) additional 
adjustment for apo(a) level; (5) additional adjustment for 
corrected LDL-C; (6) including only Lp(a) measurements 
assessed at the 5-year follow-up; (7) excluding people 
with HbA1c >6.5%; and 8) excluding the first 5 years of 
follow-up.
We further examined the potential influence of reverse 
causality using Model 3, plotting time-dependent HRs 
for Lp(a), with 95% CIs. The data were broken into time-
dependent strata (2  year intervals) for Lp(a), and the 
coefficient for each time interval accounted for indi-
viduals from that time point until the end of follow-up, 
while the coefficients of the remaining covariates are 
assumed to be constant across strata. The proportional-
hazards assumption for each covariate in Model 3 with 
time-dependent intervals for Lp(a) was tested. Statistical 
analyses were performed in R Statistical Software (ver-
sion 3.3.1) [27].
Meta‑analysis search strategy and selection criteria
We identified studies published from 1975 to October 
2016 through a systematic literature search of Medline, 
Embase and Web of Science using the terms “diabe-
tes” or “diabetes mellitus” or “Diabetes Mellitus”[Mesh] 
(MEDLINE only), and “lipoprotein(a)” or “Lp(a)” or 
“Lipoprotein(a)”[Mesh] (MEDLINE only). We restricted 
our search to articles published in the English language 
and reporting on humans.
All prospective cohort studies that: (1) reported on the 
association of Lp(a) and incident type-2 diabetes; and 
(2) did not select participants on the basis of having any 
previous chronic disease were eligible for inclusion in the 
study. A data extraction form was used to record patient 
and study characteristics, including sample size, number 
of diabetes cases, mean or median follow-up time, num-
ber and percent of males, mean or median age, Lp(a) 
ascertainment and diabetes ascertainment. For incident 
type-2 diabetes outcomes, summary statistics (HRs or 
odds ratios [OR] and 95% CIs) for each Lp(a) quintile 
were extracted. When a study had reported effect esti-
mates for different levels of adjustment, we extracted the 
estimate relating to the most fully adjusted model. Data 
were extracted by one investigator (EP), independently 
checked by another investigator (KM) and discrepan-
cies were resolved by discussion and by adjudication of a 
third investigator (PW).
Meta‑analysis statistical analysis
Effect sizes and standard errors for the risk of diabetes 
were pooled across the studies using fixed-effect meta-
analysis weighted by the inverse variance. Only studies 
reporting incident diabetes risk according to quintiles of 
Lp(a) concentration were included in the meta-analysis. 
Four meta-analyses were run with each quintile of Lp(a) 
concentration from 1 to 4 treated as a separate outcome 
and compared to quintile 5. Effect sizes and standard 
errors were first log-transformed and studies reporting 
effect sizes in relation to quintile 1 were transformed to 
give effect sizes in relation to quintile 5. Heterogeneity 
between studies within each Lp(a) quintile was quanti-
fied using the I2 statistic [28]. Weighted mean Lp(a) con-
centrations in each quintile were approximated by taking 
the average of the median Lp(a) concentrations in each 
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quintile, weighted by the number of participants in each 
study, for those studies that reported median Lp(a) con-
centrations by quintile. Since quintiles of Lp(a) concen-
tration are not independent, we undertook a sensitivity 
analysis using multivariate meta-analysis which can com-
bine effect sizes from multiple studies across related 
parameters [29–31]. Most published studies do not report 
covariance matrices needed for estimating within-study 
correlation in multivariate meta-analysis so we fitted 
three models in which we changed the within-study cor-
relation to reflect a range of plausible values (0.2, 0.5 and 
0.8). Analyses were undertaken using Stata version 14.2.
Results
Bruneck study
Baseline characteristics for the 815 Bruneck participants 
with recorded baseline Lp(a) measurements and with-
out diabetes at baseline are provided in Table  1. Mean 
age was 58  years (SD =  11) and 403 (50%) participants 
were men. The median baseline Lp(a) level for individuals 
was 8.9 mg/dL (IQR 4.5–22.2). In a cross-sectional analy-
sis, Lp(a) concentration was associated with the number 
of KIV repeats, LDL-C corrected for Lp(a)-cholesterol, 
and HbA1c (adjusted mean differences in Lp(a): −38.0, 
+26.0, +12.0%, respectively; all P ≤ 0.01).
Over 20 years of follow-up, 94 incident events of type-2 
diabetes were recorded. The HRs for type-2 diabetes, 
according to Lp(a) quintiles, are shown in Table  2. After 
adjusting for age and sex, there was an increased risk of 
type-2 diabetes for those with Lp(a) concentrations in quin-
tile 2 (median Lp(a) = 5.1 mg/dL) compared to quintile 5 
(51.9  mg/dL) (HR =  1.90 [1.04–3.45]; Table  2). Although 
the HRs were higher for quintiles 1 (2.3 mg/dL), 3 (8.8 mg/
dL) and 4 (17.5  mg/dL) compared to quintile 5, these 
results were not statistically significant. HRs strengthened 
somewhat following further adjustments in Models 2 and 
Table 1 Baseline characteristics of participants and cross-sectional associations with lipoprotein(a) (n = 815)
BMI body mass index, HDL-c high density lipoprotein cholesterol, HOMA-IR homeostatic model assessment-insulin resistance, hsCRP high sensitivity c-reactive protein, 
KIV kringle IV, SD standard deviation, SES socioeconomic status, WHR waist hip ratio
* P ≤ 0.01
** P ≤ 0.001
a Single measurement in 1990
b LDL-C corrected by removing Lp(a) multiplied by 0.45 [23]
Baseline variables Mean (SD), median  
(25th–75th), or n (%)
Age‑ and sex‑adjusted % mean difference  
in Lp(a) (95% CI) per SD higher level  
or compared to reference group
Baseline Lp(a), mg/dLa 8.9 (4.5–22.2) –
Apo(a) isoform size, KIV repeats 25 (4.5) −38.0 (−41.0, −34.0)**
Age, mean (SD), years 58 (11.0) 1.3 (−4.6, 7.6)
Male sex, % 403 (49.5) −2.1 (−13.2, 10)
Current smoking, % 199 (24.4) 13.0 (−1.8, 30.0)
Alcohol consumption, gram/week 10 (0–50) −1.4 (−8.0, 5.7)
Physical activity, Baecke score
 Low 148 (18.2) [Reference]
 Medium 312 (38.3) −16.0 (−29.0, 0.65)
 High 355 (43.6) 0.1 (−16.0, 19.0)
SES
 Low 504 (61.8) [Reference]
 Medium 173 (21.2) −0.1 (−14.0, 17.0)
 High 138 (16.9) −17.0 (−30.0, −1.0)
Systolic blood pressure, mmHg 144 (21.0) 1.6 (−5.0, 8.6)
BMI, kg/m2 25 (3.7) 2.3 (−3.7, 8.7)
WHR 0.89 (0.07) 4.9 (−2.5, 13.0)
LDL-C, mg/dLb 137 (38.0) 26.0 (19.0, 33.0)**
Triglycerides, mg/dL 130 (78.4) 1.9 (−7.6, 4.3)
hsCRP, mg/L 0.14 (0.084–0.28) 0.3 (−5.7, 6.6)
HOMA-IR 2.5 (1.6–3.7) −1.6 (−7.4, 4.7)
HbA1c, % 5.4 (0.4) 12.0 (5.3, 20.0)*
Fasting glucose, mg/dL 97 (9.5) 0.7 (−5.3, 7.1)
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3, but the overall patterns remained the same. In the most 
fully adjusted model, Model 3, those in second quintile of 
Lp(a) concentration had 2.24-times the risk of develop-
ing type-2 diabetes than those with the highest Lp(a) lev-
els (HR  =  2.24 [1.22–4.10]; Table  2). When Lp(a) was 
included in the model as a linear predictor, a standard devi-
ation lower log Lp(a) concentration was associated with a 
12% higher type-2 diabetes risk (HR  =  1.12 [0.95–1.32], 
P  =  0.171; Table  2) in Model 3. In analyses focusing on 
apo(a) isoform size as an exposure, we found no associa-
tion with incident type-2 diabetes (HR comparing small vs. 
large isoforms = 1.01 [0.97–1.06], P = 0.584).
The HRs per standard deviation lower log Lp(a) con-
centration visually decreased with longer follow-up time 
for Model 3 (Fig.  1), although this trend was not signifi-
cant when testing the proportional-hazards assumption. 
We observed results similar to the principal analysis after 
further adjustment for markers of glycemia, apo(a) and 
LDL-C, when excluding participants with HbA1c  >6.5%, 
or when accounting for possible undiagnosed prevalent 
cases by excluding the first 5 years of follow-up (Fig.  2). 
We further re-ran Model 3 using the 1995 Lp(a) measure-
ments instead of usual levels to investigate whether the dif-
ference in how Lp(a) was measured at follow-up compared 
to baseline influenced the results, finding little difference 
compared to the main results (HR = 1.10 [0.91–1.34]).
Meta‑analysis of the association between Lp(a) quintiles 
and diabetes risk
A total of 1582 titles/abstracts were screened for eligibil-
ity with 47 eligible for full-text review (Additional file 1: 
Figure A1). Of these, five articles [5–9] reporting on four 
unique studies were found to be eligible for inclusion 
in the meta-analysis. Table  3 shows the characteristics 
of the included studies. All studies reported on middle-
aged individuals with the median age being similar across 
studies and all studies used multiple data sources to 
verify diabetes cases (Table 3). All cohorts were sourced 
from the general population except for the Women’s 
Health Study (WHS) [5] which was comprised of health 
care professionals. The studies included in the meta-anal-
ysis were from Western countries and included Cauca-
sian participants.
Although the range of Lp(a) concentrations in each 
quintile varied between studies, all studies showed some 
evidence of an inverse-relationship between Lp(a) con-
centration and risk of type-2 diabetes, although the 95% 
CIs often included the null (Additional file 1: Table A1). 
Broadly similar results were seen in the Turkish Adult 
Risk Factor Study (TARF) [8] which reported risk accord-
ing to tertiles, but not quintiles, of Lp(a) concentration 
and was not included in the meta-analysis (Additional 
file 1: Table A1).
Figure  3 shows the risk of incident type-2 diabetes 
across quintiles of Lp(a) concentrations after meta-
analysis. A total 74,575 participants from four prospec-
tive studies were included in the meta-analysis. The risk 
of incident type-2 diabetes was significantly higher in 
the first two quintiles (mean Lp(a) = 3.3 and 7.0 mg/dL, 
respectively) of Lp(a) concentration compared to quintile 
5 (62.9 mg/dL). The HRs in each quintile of Lp(a) concen-
tration, relative to quintile 5, were: 1.28 (1.14–1.43) for 
quintile 1; 1.14 (1.01–1.28) for quintile 2; 1.04 (0.92–1.17) 
for quintile 3; and 1.09 (0.97–1.23) for quintile 4. There 
was no evidence of heterogeneity between studies in any 
of the quintiles (P > 0.05 in each quintile 1–4 compared 
Table 2 Hazard ratios (95% CI) for risk of incident type-2 diabetes according to usual levels of lipoprotein(a) concentra-
tion
Model 1 was adjusted for age and sex. Model 2 was additionally adjusted for alcohol consumption, BMI, smoking, SES and physical activity. Model 3 was adjusted for 
the same factors as Models 1 and 2 plus systolic blood pressure, HDL-C, log hsCRP and waist–hip ratio
Usual Lp(a) concentration are predicted long-term average levels of Lp(a) estimated by regressing the log-transformed Lp(a) values measured at the 5-year follow-up 
on the log-transformed Lp(a) baseline values
CI confidence intervals, BMI body mass index, HDL-C high density lipoprotein cholesterol, HR hazard ratio, hsCRP high sensitivity c-reactive protein, Lp(a) lipoprotein(a), 
SD standard deviation, SES socioeconomic status




HR (95% CI) 
Model 1
P value HR (95% CI) 
Model 2




 1 20 2.3 (0.8–3.6) 1.36 (0.74, 2.48) 0.326 1.35 (0.73, 2.49) 0.336 1.37 (0.74, 2.53) 0.311
 2 26 5.1 (3.7–6.6) 1.90 (1.04, 3.45) 0.036 2.15 (1.18, 3.93) 0.013 2.24 (1.22, 4.10) 0.009
 3 17 8.8 (6.7–12.3) 1.42 (0.76, 2.66) 0.269 1.34 (0.71, 2.51) 0.365 1.43 (0.75, 2.71) 0.276
 4 18 17.5 (12.5–26.9) 1.05 (0.53, 2.08) 0.896 1.02 (0.51, 2.03) 0.961 1.01 (0.51, 2.01) 0.981
 5 13 51.9 (27.1–316.2) [Reference] [Reference] [Reference]
Per SD lower log 
Lp(a)
1.10 (0.93, 1.29) 0.253 1.12 (0.95, 1.32) 0.176 1.12 (0.95, 1.32) 0.171
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Fig. 1 Change in the hazards ratios (95% CI) per SD lower log lipoprotein(a) for incident diabetes mellitus by follow-up time in the Bruneck Study. 
CI confidence intervals. Hazard ratios are shown for Model 3, adjusted for age, sex, alcohol consumption, BMI, smoking status, socioeconomic status, 
physical activity, systolic blood pressure, HDL cholesterol, log hsCRP and waist–hip ratio
Fig. 2 Sensitivity analyses showing the hazards ratios (HR) and 95% confidence intervals for the risk of incident type 2 diabetes per SD lower log 
lipoprotein(a) in the Bruneck Study. HbA1c hemoglobin A1c, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein(a). Hazard ratios are per 
quintile increase of standardized log lipoprotein(a). Model 3 was adjusted for age, sex, alcohol consumption, body mass index, smoking status, 
socioeconomic status, physical activity, systolic blood pressure, HDL cholesterol, log high sensitivity c-reactive protein and waist–hip ratio. Sensitiv-
ity analyses models as shown
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to quintile 5). The sensitivity analyses using multivariate 
meta-analysis with varying estimates of within-study cor-
relations showed similar HRs in each quintile and similar 
overall patterns but with larger 95% confidences inter-
vals than those observed in the main analysis (Additional 
file 1: Figure A2).
Table 3 Summary characteristics of studies included in the literature-based meta-analysis
CCHS Copenhagen City Heart Study, CGPS Copenhagen General Population Study, EPIC-Norfolk European Prospective Investigation of Cancer-Norfolk, WHS Women’s 
Health Study
a Self-report validated by linkage to other sources
b American Diabetes Association criteria and/or use of diabetes medication










Bruneck study Bruneck Italy Mean = 58 (11) 403 (50) 815 94 Median = 20.0 b
Mora et al. [5] WHS US Mean = 55 (7) 0 (0) 26,746 1670 Median = 13.3 a
Kamstrup et al. [6] CCHS and CGPS Denmark Median = 58 (47–67) 34,691 (45) 29,106 2157 Not provided a
Ye et al. [9] EPIC-Norfolk UK Mean = 59 (9) 8248 (45) 17,908 593 Mean = 9.8 a
Fig. 3 Meta-analysis of reported risk ratios for incident type-2 diabetes per quintile of Lp(a) concentration. Based on a fixed-effect meta-analysis 
of data from: the Bruneck study (Model 3, adjusted for age, sex, alcohol consumption, body mass index, smoking status, socioeconomic status, 
physical activity, systolic blood pressure, HDL cholesterol, log hsCRP and waist–hip ratio); the Copenhagen City Heart Study and the Copenhagen 
General Population Study (results adjusted for: age, sex, total cholesterol, HDL cholesterol, triglyceride concentrations, systolic blood pressure, body 
mass index, smoking status, lipid lowering therapy, and postmenopausal status and hormone replacement therapy among women); the European 
Prospective Investigation of Cancer-Norfolk study (results adjusted for: age, sex, body mass index, alcohol, smoking status, diastolic and systolic 
blood pressure, family history of diabetes, physical activity, education, total cholesterol, LDL cholesterol, prevalent cancer, CHD or stroke, antihyper-
tension medication, lipid-lowering drugs, and CRP); and the Women’s Health Study (results adjusted for: age, race, RCT assignment, smoking status, 
menopausal status, postmenopausal hormone use, family history of diabetes, blood pressure, body mass index, hemoglobin A1c). Studies are 
weighted using the inverse variance method. Mean Lp(a) concentrations in each quintile were estimated by taking the average of the median Lp(a) 
concentrations in each quintile across studies, weighted by the number of participants, excluding the Women’s Health Study which did not report 
median Lp(a) concentrations by quintile
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Discussion
The results from this study provide evidence of an 
increased risk of type-2 diabetes in those with low levels 
of Lp(a) concentration compared to those with the high-
est Lp(a) concentration. Overall, there was no evidence of 
a linear association (P = 0.171) between Lp(a) concentra-
tion and incident type-2 diabetes in the Bruneck study. 
These results were robust to a series of sensitivity analy-
ses assessing residual confounding. We also found no evi-
dence of reverse causality after excluding the first 5 years 
of follow-up or when examining HRs plotted by follow-
up time. Although visually the HRs appeared to increase 
over time, the confidence intervals overlapped between 
time points and the test for trend was not significant. 
Although there was no overall association observed in 
the Bruneck study, when we meta-analysed these results 
with results from previous prospective studies to gain 
statistical power, we found a higher risk of type-2 diabe-
tes among people with Lp(a) concentrations in the lowest 
2 quintiles (mean Lp(a) <7.0 mg/dL) compared to those 
in quintile 5 (62.9 mg/dL). This relationship was strongest 
in those with the lowest levels of Lp(a); those in the first 
quintile of Lp(a) concentration (mean Lp(a)  =  3.3  mg/
dL) had a 28% (HR = 1.28 [1.14–1.43]) increased risk of 
type-2 diabetes compared to those in the highest quin-
tile. Overall we found a modest association between low 
Lp(a) levels and the risk of incident diabetes in Cauca-
sian populations from four Western countries. The level 
of risk may be higher in higher-risk populations or in 
other ethnicities, as observed in the TARF study which 
found a ~twofold higher risk of incident type-2 diabetes 
among participants in the lowest vs. those in the highest 
tertile of Lp(a) concentration [8]. A large Chinese study 
observed an odds ratio of 1.37 for prevalent diabetes for a 
comparison of the lowest vs. the higher quartile of Lp(a) 
concentration, but was limited due to its cross-sectional 
design [32].
Two MR studies have previously attempted to address 
the question of whether Lp(a)-type-2 diabetes relation-
ship is causal [6, 9]. Both studies showed no association 
between Lp(a) concentrations and risk of diabetes using 
the genetic variant rs10455872 as an instrumental varia-
ble. These findings were supported by a further study [33] 
that investigated the association between lowered Lp(a) 
levels and a range of cardiometabolic conditions, finding 
no association between a genetic risk score of 4 variants 
in the LPA gene (rs10455872, rs3798220, rs41272114 and 
rs143431368) and type-2 diabetes. However, a key limi-
tation of this approach is that the main genetic variant 
(rs10455872) tags individuals with a broad range of Lp(a) 
concentrations: carriers of the variant, representing the 
high Lp(a) concentration group, had a median concentra-
tion of 61 mg/dL (IQR 46–82) while non-carriers had a 
median concentration of 11  mg/dL (IQR 5–23) [6]. The 
Lp(a) concentration of this non-carrier group captures 
the Lp(a) concentrations from quintiles 1–4. Grouping 
together people with such a broad range of Lp(a) concen-
trations may obscure associations seen only in the low-
est Lp(a) concentrations and may account for the lack 
of association in the MR studies, as discussed by Lam-
ina and Kronenberg [15]. In our meta-analysis, we only 
observed an increased risk of diabetes in people with 
Lp(a) concentrations in the lowest two quintiles. The 
rs10455872 variant cannot distinguish between these low 
levels of Lp(a) and is therefore not an appropriate proxy 
for examining the relationship between very low levels of 
Lp(a) concentration and diabetes risk [15].
Furthermore, Kamstrup and Nordestgaard [6] used 
the sum of KIV-2 repeats as a better indicator of Lp(a) 
plasma concentration than the rs10455872 variant, show-
ing that individuals in the highest quintile of the geneti-
cally determined sum of KIV-2 repeats (that are more 
likely to have low or medium Lp(a) concentrations), have 
a 16% increased risk of diabetes compared to quintiles 
1–4 of KIV-2 repeats (OR 1.16 [1.05–1.28]). The genetic 
instrument of the sum of KIV-2 repeats is not a perfect 
measure since it is a sum of two alleles which can be 
quite heterogeneous (one allele with a low and one with 
a high number of KIV-2 repeats, or both with a medium 
sized number of repeats) and it ignores that 30–50% of 
individuals express only one apo(a) isoform in plasma 
although they are clearly heterozygote at the DNA level. 
In the present study we found no evidence of an associa-
tion between isoform size and diabetes risk (HR = 1.01 
[0.97–1.06] for large isoform size compared to small iso-
forms), possibly due to a lack of power. A difference in 
the methods is that we used gel electrophoresis in the 
Bruneck Study that gives allele-specific information, 
whereas the PCR method used in the Copenhagen stud-
ies [6] summates the size of both alleles and likely weak-
ens the power of such analyses due to regression to the 
mean of apo(a) isoform size. Furthermore, this method 
has been shown to correlate only modestly with allele 
specific methods of apo(a) isoform determination [34].
The causality of the relationship between Lp(a) con-
centration and diabetes risk has not yet been sufficiently 
investigated and further studies using genetic vari-
ants that selectively tag low concentrations of Lp(a) are 
needed. Furthermore, the mechanisms through which 
Lp(a) might be inversely associated with diabetes risk 
are not yet clear. There is some evidence that Lp(a) is a 
marker of, or might be involved in, the development of 
insulin resistance. Previous studies have shown that 
lower levels of Lp(a) concentration and large apo(a) iso-
form size are associated with higher insulin levels [35], 
and that insulin can inhibit the transcription of apo(a) 
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in monkey hepatocytes [36]. It has also been speculated 
[37] that the inverse association of Lp(a) with diabetes 
may result from increased oxidative stress, oxidation of 
Lp(a) phospholipids, and subsequent low-grade inflam-
mation and autoimmune activation. Recent evidence 
demonstrated causal inverse relationships for LDL cho-
lesterol [38] and inverse associations of LDL particle size 
[39] with incident type-2 diabetes, and it may be hypoth-
esised that the association of Lp(a) is partly mediated via 
the LDL pathway.
With the recent development of drugs that selectively 
lower Lp(a) levels [10], Lp(a) could become a clinical tar-
get for reducing CVD risk. To date, results from three 
trials have shown no effect on glucose with significant 
lowering of Lp(a) to  >90% [10, 40]. Although the effect 
of such treatment on diabetes risk is not known, Lp(a) 
lowering therapy would likely only be used in people 
with highly elevated Lp(a) levels and few patients would 
be treated to low Lp(a) levels of <7 mg/dL where the risk 
seems to increase in the meta-analysis results. This is not 
the first example of a contrasting relationship between a 
lipid subclass and risk of coronary heart disease (CHD) 
and diabetes. Evidence from MR studies [41] and stud-
ies of familial hypercholesterolemia (a genetic condition 
resulting in high levels of plasma LDL-C) [42] show a 
causal relationship between LDL-C and increased CHD 
risk but a decreased risk of type-2 diabetes. While statins, 
which lower LDL-C levels, have been shown to substan-
tially decrease the risk of CVD, there is evidence that 
they increase the risk of type-2 diabetes [43]. However, 
this increased absolute risk of diabetes is considered to 
be low and does not outweigh the benefits of statins in 
reducing CVD events [43]. Further evidence of this is 
provided by a study of familial hypobetalipoproteine-
mia which showed no increase in type-2 diabetes among 
people with genetically determined low levels of LDL-C 
[42]. A recent MR study using genetic variants for pro-
protein convertase subtilisin-kexin type 9 (PCSK9) and 
3-hydroxy-3-methylglutaryl-coenzyme A reductase 
(HMGCR), that mimic the effects of lowering LDL-C lev-
els, showed an increased risk of diabetes with lower LDL-
C. However, both prevalent and incident diabetes cases 
were analysed together, and, notably, among people with 
normal fasting glucose levels at baseline, there was no 
increased risk of incident diabetes with LDL-C lowering 
[44].
The keys strengths of our study using the Bruneck data 
include: long follow-up time (20  years), representative-
ness of the general community and availability of a wide 
range of measured clinical factors, allowing us to accu-
rately ascertain type-2 diabetes as well as investigate the 
role of reverse-causality and residual bias. Although the 
Bruneck sample size was small and the precision of the 
estimated association measures was low, we were able 
to meta-analyse these results with previous prospective 
studies to provide a more precise estimate of the associa-
tion between low levels of Lp(a) concentration and risk of 
type-2 diabetes. Lp(a) concentration is largely stable over 
time and, to account for any residual regression dilution 
bias, we estimated long-term usual levels of Lp(a). We 
were unable to account for any effect of fasting status on 
Lp(a) concentrations since this varied across the included 
studies and was not always reported. However, it has 
been previously found that normal food intake does not 
affect median Lp(a) levels [45], indicating that fasting sta-
tus is unlikely to have impacted the effect sizes estimated 
in the meta-analysis. No information on within-study 
variability was available for the previously published pro-
spective studies which limited our ability to account for 
correlations within the Lp(a) quintiles in the meta-anal-
ysis. However, the measures of association estimated in 
the sensitivity analyses using multivariate meta-analysis 
were consistent with the main results. Weighted mean 
Lp(a) concentration in each quintile for the meta-anal-
yses could only be estimated using data from 3/4 stud-
ies as median Lp(a) levels per quintile were not reported 
for one of the studies (WHS). We were limited to using 
available summary data on the Lp(a)-diabetes relation-
ship reported in quintiles in previous studies, and were 
unable to undertake more sophisticated analyses to 
assess the shape of the relationship. Furthermore, there 
were inconsistencies between studies in which confound-
ers were adjusted for, however these adjustments slightly 
strengthened, rather than weakened, the effect estimates 
in most studies.
Conclusions
Our study provides evidence to support the hypoth-
esis that Lp(a) concentration is inversely associated with 
development of type-2 diabetes, in people without previ-
ous diabetes. That we only observed an increased risk of 
diabetes in people with Lp(a) concentrations in the low-
est two quintiles (~mean Lp(a) levels of <7 mg/dL) sug-
gest that the use of Lp(a) lowering therapies would not 
be in conflict with these findings if provided therapies 
do not lower Lp(a) levels beyond those observed in these 
lowest two quintiles.
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